Headshot of Lewis Cantley

Lewis Cantley, Ph.D.

Professor of Cell Biology (HMS)
Dana-Farber Cancer Institute
TBA--

Lew Cantley is widely known for his many seminal discoveries in signaling and metabolism, including the identification of PI3 kinase and its role in transformation, as well as groundbreaking work unraveling the complexities of protein kinase signaling--his work has had major impact across virtually every aspect of cancer cell biology. For those of you who are new to the department, Lew was a Cell Bio faculty member from 1992-2003 before transitioning to the then newly formed HMS Department of Systems Biology in 2003. In 2012, Lew was recruited to Weill Cornell in New York City, where he served as Director of the Meyer Cancer Center. There, he built a remarkable program focused on the intersection of metabolism and signaling in cancer.

Lew rejoined the Department of Cell Biology at HMS and the DFCI-Cancer Cell Biology in 2022.  

Dana Farber Cancer Institute

Cancer Cell Biology

Faculty Assistant

Lewis C. Cantley.
Authors: Authors: Cantley LC.
Curr Biol
View full abstract on Pubmed
The antiproliferative cytostatic effects of a self-activating viridin prodrug.
Authors: Authors: Smith A, Blois J, Yuan H, Aikawa E, Ellson C, Figueiredo JL, Weissleder R, Kohler R, Yaffe MB, Cantley LC, Josephson L.
Mol Cancer Ther
View full abstract on Pubmed
Understanding the Warburg effect: the metabolic requirements of cell proliferation.
Authors: Authors: Vander Heiden MG, Cantley LC, Thompson CB.
Science
View full abstract on Pubmed
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Authors: Authors: Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC.
Mol Cell
View full abstract on Pubmed
Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis.
Authors: Authors: Schweitzer MH, Zheng W, Organ CL, Avci R, Suo Z, Freimark LM, Lebleu VS, Duncan MB, Vander Heiden MG, Neveu JM, Lane WS, Cottrell JS, Horner JR, Cantley LC, Kalluri R, Asara JM.
Science
View full abstract on Pubmed
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
Authors: Authors: Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS.
J Clin Oncol
View full abstract on Pubmed
Bidirectional transport of amino acids regulates mTOR and autophagy.
Authors: Authors: Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley LC, Finan PM, Murphy LO.
Cell
View full abstract on Pubmed
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
Authors: Authors: Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC.
Mol Cell
View full abstract on Pubmed
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Authors: Authors: Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.
Nat Med
View full abstract on Pubmed
PI3K enters beta-testing.
Authors: Authors: Shaywitz AJ, Courtney KD, Patnaik A, Cantley LC.
Cell Metab
View full abstract on Pubmed